Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines
Bowen, J. E.; Sprouse, K. R.; Walls, A. C.; Mazzitelli, I. G.; Logue, J. K.; Franko, N. M.; Ahmed, K.; Shariq, A.; Cameroni, E.; Gori, A.; Bori, A.; Posavad, C. M.; Dan, J. M.; Zhang, Z.; Weiskopf, D.; Sette, A.; Crotty, S.; Talat Iqbal, N.; Corti, D.; Geffner, J.; Grifantini, R.; Chu, H. Y.; Veesler, D.
Show abstract
The SARS-CoV-2 Omicron variant of concern comprises three sublineages designated BA.1, BA.2, and BA.3, with BA.2 steadily replacing the globally dominant BA.1. We show that the large number of BA.1 and BA.2 spike mutations severely dampen plasma neutralizing activity elicited by infection or seven clinical vaccines, with cross-neutralization of BA.2 being consistently more potent than that of BA.1, independent of the vaccine platform and number of doses. Although mRNA vaccines induced the greatest magnitude of Omicron BA.1 and BA.2 plasma neutralizing activity, administration of a booster based on the Wuhan-Hu-1 spike sequence markedly increased neutralizing antibody titers and breadth against BA.1 and BA.2 across all vaccines evaluated. Our data suggest that although BA.1 and BA.2 evade polyclonal neutralizing antibody responses, current vaccine boosting regimens may provide sufficient protection against Omicron-induced disease.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster 97%
- Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers 96%
- Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains 96%
Similar papers in this journal
- Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera 96%
- Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory 95%
- Rapid development of an inactivated vaccine for SARS-CoV-2 95%
Similar papers in this journal
- A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants 96%
- Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination 96%
- Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants 95%
Similar papers in this journal
- Antibody and memory B-cell immunity in a heterogeneously SARS-CoV-2 infected and vaccinated population 96%
- Anamnestic Humoral Correlates of Immunity Across SARS-CoV-2 Variants of Concern 96%
- Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.